Q1 Earnings Forecast for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for CorMedix in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of $0.23 per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.73 EPS, FY2026 earnings at $2.50 EPS, FY2027 earnings at $3.20 EPS and FY2028 earnings at $3.65 EPS.

CorMedix (NASDAQ:CRMD) last announced its quarterly earnings data on Tuesday, March 25th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. The firm had revenue of $30.00 million for the quarter, compared to analysts’ expectations of $27.46 million. CorMedix’s revenue for the quarter was up 29900.0% on a year-over-year basis.

Several other research firms have also issued reports on CRMD. Royal Bank of Canada restated an “outperform” rating and set a $12.00 price target on shares of CorMedix in a research report on Wednesday. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of CorMedix in a report on Tuesday. Needham & Company LLC reduced their price target on CorMedix from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Leerink Partners assumed coverage on CorMedix in a research report on Friday, March 7th. They issued an “outperform” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.14.

CorMedix Stock Performance

Shares of CorMedix stock opened at $6.74 on Friday. The stock has a market capitalization of $408.96 million, a price-to-earnings ratio of -8.32 and a beta of 1.53. The company has a fifty day moving average of $10.43 and a 200-day moving average of $9.89. CorMedix has a 52-week low of $3.61 and a 52-week high of $13.85.

Hedge Funds Weigh In On CorMedix

A number of institutional investors have recently bought and sold shares of CRMD. Vanguard Group Inc. grew its holdings in shares of CorMedix by 10.1% during the 4th quarter. Vanguard Group Inc. now owns 3,378,191 shares of the company’s stock worth $27,363,000 after acquiring an additional 309,514 shares during the period. Elliott Investment Management L.P. grew its stake in CorMedix by 85.1% in the fourth quarter. Elliott Investment Management L.P. now owns 2,870,632 shares of the company’s stock worth $23,252,000 after purchasing an additional 1,320,109 shares during the period. Geode Capital Management LLC raised its holdings in CorMedix by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 1,392,820 shares of the company’s stock worth $11,284,000 after purchasing an additional 108,356 shares in the last quarter. State Street Corp lifted its position in CorMedix by 0.8% during the third quarter. State Street Corp now owns 1,225,756 shares of the company’s stock valued at $9,904,000 after buying an additional 10,204 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of CorMedix by 14.4% during the 4th quarter. Northern Trust Corp now owns 511,565 shares of the company’s stock valued at $4,144,000 after buying an additional 64,243 shares in the last quarter. 34.18% of the stock is owned by institutional investors.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.